Synthetic TLR-3 ligands
ESMO – December 2021 – Presented by Dr Bettina Werle
Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
OTS – September 2021 – Dr Marc Bonnin
First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination
OTS – September 2021 – Dr Sylvain Thierry
First rationally designed Toll-like Receptor 3 agonist “TL-532”induces apoptosis specific of tumor cells and long-lasting anti-tumor Immunity
EACR – June 2021 – Dr Sylvain Thierry
Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
EACR – June 2021 – Dr Marc Bonnin
TL-532, the first rationally designed TLR3 agonist creates long-lasting tumor specific immunity in vivo
Sting & TLR-targeted therapies – May 2021 – Presented by Dr Bettina Werle
Recent Comments